DH vs. CERT, CXM, BBAI, RPD, AVDX, LSPD, DAVA, JAMF, EVCM, and OPRA
Should you be buying Definitive Healthcare stock or one of its competitors? The main competitors of Definitive Healthcare include Certara (CERT), Sprinklr (CXM), BigBear.ai (BBAI), Rapid7 (RPD), AvidXchange (AVDX), Lightspeed Commerce (LSPD), Endava (DAVA), Jamf (JAMF), EverCommerce (EVCM), and Opera (OPRA). These companies are all part of the "computer software" industry.
Definitive Healthcare vs.
Certara (NASDAQ:CERT) and Definitive Healthcare (NASDAQ:DH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.
Certara has a net margin of -8.34% compared to Definitive Healthcare's net margin of -142.38%. Certara's return on equity of 3.43% beat Definitive Healthcare's return on equity.
Certara and Definitive Healthcare both received 24 outperform votes by MarketBeat users. However, 33.33% of users gave Certara an outperform vote while only 27.91% of users gave Definitive Healthcare an outperform vote.
Certara has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Definitive Healthcare has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
In the previous week, Certara had 1 more articles in the media than Definitive Healthcare. MarketBeat recorded 4 mentions for Certara and 3 mentions for Definitive Healthcare. Certara's average media sentiment score of 1.05 beat Definitive Healthcare's score of 0.51 indicating that Certara is being referred to more favorably in the media.
Certara presently has a consensus price target of $15.92, suggesting a potential upside of 20.86%. Definitive Healthcare has a consensus price target of $5.72, suggesting a potential upside of 16.31%. Given Certara's stronger consensus rating and higher probable upside, analysts plainly believe Certara is more favorable than Definitive Healthcare.
Certara has higher revenue and earnings than Definitive Healthcare. Certara is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.
74.0% of Certara shares are held by institutional investors. Comparatively, 98.7% of Definitive Healthcare shares are held by institutional investors. 2.4% of Certara shares are held by insiders. Comparatively, 14.8% of Definitive Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Certara beats Definitive Healthcare on 13 of the 17 factors compared between the two stocks.
Get Definitive Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for DH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Definitive Healthcare Competitors List
Related Companies and Tools
This page (NASDAQ:DH) was last updated on 2/22/2025 by MarketBeat.com Staff
